Magnitude Biosciences

Magnitude Biosciences, founded in 2016 and based in Manchester, UK, operates as a specialized CRO offering high-throughput, in vivo screening services using the C. elegans model organism. The company's core value proposition is its VivoScan™ platform, which combines automated imaging and AI/ML analysis to enable rapid, reproducible, and cost-effective compound screening from as low as $1 per compound. It serves a diverse client base from academia to large pharma, helping to de-risk early-stage drug discovery in areas like longevity and neurodegeneration. Magnitude is a private, likely revenue-generating services company, positioning itself as a partner for whole-organism screening from hit identification to mechanistic insight.

VivoScan™ High-Throughput Screening Platform and WormGazer™ automated imaging technology, utilizing C. elegans and AI/ML for whole-organism phenotypic screening.

Magnitude competes with other specialized CROs offering C. elegans services (e.g., NemaLife) and broader early-discovery providers using alternative models like zebrafish or organoids. Its differentiation lies in its automated, AI-integrated platform and focus on high-throughput, low-cost whole-organism screening.